Chronic Obstructive Pulmonary Disease Market By Type (Chronic Bronchitis, Emphysema), Treatment Type (Drugs, Surgery, Oxygen Therapy), End-User (Hospitals, Clinics, Homecare Settings), & Region for 2026-2032

Chronic Obstructive Pulmonary Disease Market Valuation - 2026-2032

Rising incidence of COPD among populations across the globe is propelling the adoption of chronic obstructive pulmonary disease. The increasing tobacco consumption among young people & rising public awareness of the usage of generic drugs is driving the market size surpass USD 21.17 Billion valued in 2024 to reach a valuation of around USD 35.3 Billion by 2032.

In addition to this, increasing expenditure on healthcare is giving services in emerging countries is spurring up the adoption of chronic obstructive pulmonary disease. Growing R&D investment by the government and large players is enabling the market grow at a CAGR of 7.28% from 2026 to 2032.

Chronic Obstructive Pulmonary Disease Market: Definition/ Overview

Chronic obstructive pulmonary disease (COPD), also known as emphysema or chronic bronchitis, is a lung disease causing restricted airflow and breathing issues. Symptoms include cough, difficulty breathing, wheezing, and tiredness. Common causes include smoking and air pollution, and those with COPD are at higher risk of other health issues. Chronic bronchitis causes inflammation of the bronchial tubes, causing swelling and the buildup of mucus, which narrows the tube's opening, making it difficult for air to enter and exit the lungs. Emphysema is the breakdown of air sacs (alveoli) at the bottom of the lung, similar to an upside-down tree with the windpipe as the trunk, bronchi as branches, and air sacs as leaves.

Chronic Obstructive Pulmonary Disease (COPD) treatment focuses on alleviating symptoms, improving quality of life, and slowing disease progression. Key components include bronchodilators to relax airway muscles and improve airflow, inhaled corticosteroids to reduce inflammation, and combination inhalers for enhanced efficacy. Pulmonary rehabilitation programs, encompassing exercise training, nutrition advice, and education, are crucial for patient empowerment and functional improvement. Supplemental oxygen therapy may be necessary for severe cases. Additionally, smoking cessation is vital to halt disease progression, while vaccinations and regular monitoring help prevent exacerbations and manage comorbidities effectively.

The future of COPD treatment will focus on personalized medicine, advanced drug delivery systems, and innovative therapies. Key trends include biologics targeting specific inflammatory pathways, gene therapy and regenerative medicine for lung tissue repair, digital health technologies like telemedicine and remote monitoring, and novel inhaler technologies and drug formulations. These advancements aim to improve outcomes and quality of life for COPD patients, enhancing patient management and adherence to treatment plans.

How will Rising Awareness of Chronic Obstructive Pulmonary Disease (COPD) Increase Adoption of Chronic Obstructive Pulmonary Disease?

Rising awareness of chronic obstructive pulmonary disease (COPD) continue to advance, there is a corresponding increase in the diagnosis and recognition of the condition globally. This heightened awareness among healthcare professionals and the public is crucial in identifying COPD at earlier stages, allowing for timely interventions and better management strategies. Consequently, there is a growing demand for improved diagnostic tools, more effective treatments, and increased research efforts aimed at understanding and combating COPD. This evolving landscape underscores the importance of education and proactive healthcare initiatives to mitigate the impact of COPD on individuals and healthcare systems, this is bolstering the growth of the market.

The rise in COPD cases globally presents a significant public health challenge, driven in part by factors such as tobacco smoking, which remains a leading risk factor for the disease. The increasing prevalence of adult smoking worldwide has contributed to a higher burden of COPD, highlighting the urgent need for comprehensive smoking cessation programs and stricter tobacco control measures. Additionally, occupational exposures to pollutants and indoor air pollution further exacerbate the risk of developing COPD. Addressing these environmental factors through regulatory policies and workplace interventions is crucial in reducing the incidence and progression of COPD, thereby improving the quality of life for affected individuals and lessening the strain on healthcare resources.

Advancements in diagnostic technologies like spirometry, CT scans, and biomarker testing have significantly improved the management of Chronic Obstructive Pulmonary Disease (COPD). These technologies enable early identification, personalized treatment plans, and improved symptom control. Additionally, therapeutic options like bronchodilators, corticosteroids, and biologic medicines have enhanced the quality of life for COPD patients. For instance, in February 2021, Sanofi and Regeneron Pharmaceuticals are conducting a Phase III clinical trial to evaluate the effectiveness and safety of itepekimab in reducing acute COPD exacerbations in former smokers, with the trial set to conclude in July 2024.

Will Rising Side Effects of Drugs Used in Treating Chronic Obstructive Pulmonary Disease (COPD) Restrain Its Application?

The rising side effects of drugs used in treating Chronic Obstructive Pulmonary Disease (COPD) significantly hinder market growth. According to the National Center for Biotechnology Information, medications such as inhaled steroids can cause oral infections, bruising, and hoarseness, which deter patient compliance and limit market expansion. Additionally, COPD patients on these medications are prone to respiratory infections like flu, colds, and pneumonia, further complicating their treatment and increasing healthcare costs.

Moreover, the complexity of COPD and the variability in patient response to treatments make drug development particularly challenging. Clinical trials, such as the Phase II TERRANOVA and GALATHEA studies, often struggle to demonstrate efficacy and safety, further impeding progress in the COPD market. This uncertainty in drug development discourages investment and slows the introduction of new therapies.

The development of new drugs for COPD is fraught with challenges, including high failure rates in clinical trials. For instance, in May 2019, benralizumab, an asthma drug, failed to reduce annual COPD exacerbation rates in patients with moderate to very severe COPD. Such setbacks highlight the difficulties in discovering effective treatments, limiting market growth prospects.

Complications associated with COPD, including depression, heart problems, high blood pressure in lung arteries, and lung cancer, also pose challenges to effective management and market growth. The severity of these complications necessitates comprehensive treatment approaches, which are often costly and resource-intensive, restraining market growth.

Category-Wise Acumens

Which Factors Contribute to the Dominance of Drugs Segment in Chronic Obstructive Pulmonary Disease Market?

The drugs segment dominates the chronic obstructive pulmonary disease (COPD) market, primarily due to the widespread use of bronchodilators. Bronchodilators, both short-acting and long-acting, hold a largest market share. They are crucial for managing COPD symptoms by relaxing airways and providing rapid relief from bronchospasms and exacerbations. The inhaled delivery method enhances patient compliance, making them a preferred choice for both patients and healthcare providers. As COPD progresses and lung function declines, bronchodilators become even more significant in managing symptoms and preventing exacerbations.

Corticosteroids are essential COPD drugs that reduce airway inflammation and mucus production. They are often used in combination with bronchodilators, particularly in severe COPD patients or those with frequent exacerbations. They help alleviate symptoms and improve lung function over time, but long-term use may have potential side effects, requiring careful healthcare management.

Phosphodiesterase type 4 (PDE4) inhibitors represent a newer addition to COPD treatment options. These medications work by reducing inflammation and relaxing the airways, similar to corticosteroids but through a different mechanism. PDE4 inhibitors are typically prescribed for patients with severe COPD and a history of exacerbations despite bronchodilator and corticosteroid therapy. Their role in managing COPD involves improving lung function and reducing exacerbation frequency, contributing to overall disease control and patient well-being.

The COPD market comprises various drug classes, including bronchodilators for immediate symptom relief, corticosteroids for inflammation management, and PDE4 inhibitors for symptom relief, each playing a crucial role in managing COPD symptoms and enhancing patient outcomes.

Which Factors Enhance the Use of Chronic Obstructive Pulmonary Disease in Hospitals?

Hospitals dominate the chronic obstructive pulmonary disease (COPD) market, with specialized departments like pulmonology and respiratory therapy, and advanced diagnostic capabilities like pulmonary function tests and imaging, ensuring accurate diagnosis and disease monitoring.

Hospitals offer a multidisciplinary approach to COPD management, involving pulmonologists, respiratory therapists, nurses, and rehabilitation specialists. They provide comprehensive care, addressing both medical and supportive needs. They offer a range of COPD treatments, including bronchodilators, corticosteroids, oxygen therapy, and surgical interventions. Hospitals also participate in clinical trials for innovative therapies.

Hospitals provide 24/7 emergency services, crucial for COPD patients experiencing sudden exacerbations or respiratory distress. This accessibility ensures prompt medical intervention and reduces morbidity and mortality associated with severe COPD complications.

Country/Region-wise Acumens

Will Rising Prevalence of COPD in North America Mature Chronic Obstructive Pulmonary Disease Market?

North America stands out as a dominant force in the global chronic obstructive pulmonary disease (COPD) market for several compelling reasons. The region boasts a high prevalence of COPD, attributed partly to historical smoking rates and environmental factors. This prevalence drives substantial demand for COPD treatments and healthcare services, making it a significant contributor to the market's size and growth.

North America benefits from advanced healthcare infrastructure and robust pharmaceutical industry capabilities. This infrastructure supports comprehensive diagnostic capabilities, including advanced imaging and pulmonary function tests, crucial for accurate COPD diagnosis and monitoring. Moreover, the region's strong research and development ecosystem fosters continuous innovation in COPD therapies, ensuring patients have access to cutting-edge treatments and medications.

Also, efforts to raise public awareness about public health and implement smoking cessation programs in countries such as the United States and Canada are aimed at reducing risk factors for COPD and improving early detection. These initiatives contribute to improved disease management and outcomes, further solidifying North America's position as a leader in the global COPD market.

Furthermore, healthcare policies and reimbursement frameworks in North America facilitate access to COPD treatments, including bronchodilators, corticosteroids, and biologics. This accessibility ensures that COPD patients receive timely and appropriate care, enhancing treatment adherence and overall health outcomes.

Will Increasing Air Pollution in Asia Pacific Drive the Growth of Chronic Obstructive Pulmonary Disease Market?

The Asia-Pacific region is expected to witness significant growth in the drugs segment of the chronic obstructive pulmonary disease (COPD) market during the forecast period due to the rising prevalence of COPD. Increasing air pollution and high smoking rates in countries like China and India contribute to a growing patient population, driving demand for effective treatments.

A rising prevalence of respiratory distress conditions is a major driver in the region. According to the World Health Organization (WHO), over 90% of COPD-related deaths occur in low and middle-income countries, highlighting the critical need for effective treatments in Asia-Pacific.

Moreover, the presence of a large aging population in the region, which is more susceptible to COPD, is fueling the demand for maintenance and rescue medications. This demographic trend is a key driver of market growth in the drugs segment.

Pharmaceutical companies are increasingly focusing on the Asia-Pacific market due to its high growth potential. Investments in local manufacturing and distribution networks, along with strategic partnerships, are expanding the availability and affordability of COPD drugs, thereby supporting market expansion in the region.

Competitive Landscape

The competitive landscape of the chronic obstructive pulmonary disease (COPD) market is characterized by intense competition and rapid innovation. Companies are focusing on developing advanced drug formulations and delivery systems to improve patient outcomes and adherence. Strategic collaborations, mergers, and acquisitions are common as firms aim to expand their market presence and leverage synergistic capabilities. Additionally, substantial investments in research and development, along with an emphasis on personalized medicine and biologics, are driving the evolution of treatment options, making the market highly dynamic and competitive. Some of the prominent players operating in the chronic obstructive pulmonary disease market include:

AstraZeneca

Boehringer Ingelheim

GlaxoSmithKline (GSK)

Novartis

Merck & Co.

Pfizer

Teva Pharmaceuticals

Sanofi

Mylan

Chiesi Farmaceutici

Sunovion Pharmaceuticals

Orion Corporation

Cipla

Reddy's Laboratories

Vectura Group

Circassia Pharmaceuticals

Theravance Biopharma

Verona Pharma

Glenmark Pharmaceuticals

Pulmatrix

Latest Developments

In January 2022, A phase 4 study comparing Yupelri (revefenacin) and Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD) is underway. The study assesses the safety of these two approved daily COPD maintenance treatments. Yupelri, a bronchodilator developed by Theravance Biopharma and Mylan, relaxes and widens lung airways, making breathing easier. It is available as an inhalable solution via a nebulizer.

In November 2021, AstraZeneca sold the rights to commercialize Tudorza (Eklira) and Duaklir to Swiss pharmaceutical business Covis Pharma Group for US$ 270 million. The products are intended for the treatment of chronic obstructive pulmonary disease (COPD).

Chronic Obstructive Pulmonary Disease Market, By Category

• Type:
• Chronic Bronchitis
• Emphysema
• Treatment Type:
• Drugs
• Bronchodilator Monotherapy
• Short-Acting Beta2-Agonists (SABAS)
• Long-Acting Beta2-Agonists (LABAS)
• Anti-Cholinergic Agents
• Anti-Inflammatory Drugs
• Oral And Inhaled Corticosteroids
• Anti-Leukotrienes
• Surgery
• Lung Volume Reduction Surgery (LVRS)
• Lung Transplant, Bullectomy
• Others
• Oxygen Therapy
• End-User:
• Hospitals
• Homecare Settings
• Clinics
• Others
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa